Results: We found KRAS mutation in only one case (2.7 %), apocrine carcinoma which was Gly12Asp (GGT> GAT) mutation. The BRAF V600 mutations were not detected in all analyzed tumors. Conclusion: We concluded that KRAS mutation was rare in triple negative breast carcinomas and high frequency of EGFR overexpression in this subtype might be related to other pathways in EGFR signaling.